Divi’s Labs Posts 46.5% Profit Jump in Q2 FY25 Earnings, Revenue and Margins Soar

For the second quarter of FY25, Divi’s Laboratories reported a significant rise in net profit. The company posted a profit of ₹510 crore, marking a 46.5% increase from ₹348 crore in Q2 FY24.

Revenue Growth of 22.5%
Divi’s Labs achieved a revenue of ₹2,338 crore in Q2 FY25, representing a 22.5% year-on-year growth. This boost reflects steady demand and strong performance across its business segments.

EBITDA and Margins on the Rise
The company’s EBITDA for the quarter climbed 49.5% YoY, reaching ₹716 crore, compared to ₹479 crore in Q2 FY24. Divi’s Labs also reported a margin increase of 500 basis points, with the margin now at 30.6%, up from 25% in the same quarter last year.

Half-Year Financial Highlights
In the 6 months ending September 30, Divi’s Labs recorded a total income of ₹4,640 crore, up from ₹3,854 crore in the same period last year. Profit after tax (PAT) for the half-year period stood at ₹940 crore, a notable rise from ₹704 crore in H1 FY24.

Forex Gain
The company saw a forex gain of ₹28 crore in the current half-year, up from ₹14 crore in the same period last year. This gain contributed positively to the overall profitability of Divi’s Laboratories.

About Divi’s Laboratories Ltd

Established in 1990, Divi’s Laboratories Ltd is a leading manufacturer and exporter of Active Pharmaceutical Ingredients (APIs), chemical intermediates, and nutraceutical ingredients. Divi’s Labs produces a range of generic APIs, custom-made APIs, intermediates, and nutraceuticals for the global pharmaceutical and nutraceutical markets. The company’s portfolio includes around 160 products that cover various therapeutic areas, featuring key ingredients like Bupropion, Gabapentin, Lacosamide, Mesalamine, Pregabalin, Quetiapine, Venlafaxine, Rivaroxaban, and nutraceutical compounds like Beta-Carotene, Lycopene, Astaxanthin, and Canthaxanthin.

On November 11, 2024, Divi’s Laboratories share price opened at ₹6,155.00 and touched the day low of ₹5,782.20 as of 10:40 AM on NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.